TITLE

HYPERCOAGULABILITY WITH MALIGNANCY

AUTHOR(S)
Waterbury, Larry S.; Hampton, James W.
PUB. DATE
April 1967
SOURCE
Angiology;Apr1967, Vol. 18 Issue 4, p197
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A case is presented of an elderly man who developed migrating thrombophlebitis prior to the discover of a primary carcinoma of the cecum with hepatic metastases. The clinical �hypercoagulable state� paralleled in vitro studies that indicated accelerated clotting. The mixing of the patient's whole blood with the whole blood of a healthy and compatible individual shortened the clotting time of the individual to that of the patient. Although the prothrombin time was prolonged by the administration of anticoagulants, there was demonstrated an increase in Factor IX (Christmas factor) activity. Increased Factor IX activity implicates the initiator factors in the mechanism of intravascular thrombosis.
ACCESSION #
16400206

 

Related Articles

  • Initial management of deep venous thrombosis in the outpatient setting. Groce, James B. // American Journal of Health-System Pharmacy;5/1/2008, Vol. 65 Issue 9, p866 

    The article relates the author's perspective concerning the management of deep venous thrombosis (DVT) with low-molecular-weight heparin (LMWH) in an outpatient setting. He contends that outpatient treatment with LMWH is well tolerated and effective and can result in overall cost savings. He...

  • Spontaneous Spinal Epidural Hematoma After Combined Urokinase and Heparin Thrombolytic Therapy for Deep Venous Thrombosis. Krieger, Nancy R.; Mehigan, John Thomas // Vascular Surgery;Jan/Feb1996, Vol. 30 Issue 1, p67 

    The literature clearly supports the view that all anticoagulation therapy is associated with a significant risk of hemorrhagic complications. Combining anticoagulation and fibrinolytic therapy further adds to this risk. Moreover, in the treatment of deep venous thrombosis the combined use of...

  • Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism. Hawkins, David // American Journal of Health-System Pharmacy;11/15/2003 Supplement 7, Vol. 60, p6 

    Discusses clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism (VTE). Mechanisms used for anticoagulation therapy; Prevention of VTE after major orthopedic surgery.

  • VENOUS THROMBOSIS IN CHILDHOOD. Balas, P.; Tripolitis, A.; Charocopos, E.; Mandalaki, R. T. // Angiology;Dec1976, Vol. 27 Issue 12, p730 

    Venous thrombosis in childhood is an extremely rare condition. The etiologic factors in childhood are different than in the adult. Generalized infection seems to play the main etiologic role, and for this reason antibiotic treatment is usually necessary. Anticoagulant treatment is mandatory;...

  • Coagulation and Cancer Therapy: The Potential of Natural Compounds. Justo, Giselle Z.; Ferreira, Carmen V. // Current Genomics;Oct2005, Vol. 6 Issue 6, p461 

    In the past few years, it has become clear that the processes of cancer metastasis and invasion are highly dependent on components of the blood coagulation cascade. Metastasis is critically dependent on the formation of new blood vessels and the role of many blood-clotting factors in tumor...

  • Do circulating tumor cells play a role in coagulation and thrombosis? Tormoen, Garth W.; Haley, Kristina M.; Levine, Ross L.; McCarty, Owen J. T. // Frontiers in Oncology;Aug2012, Vol. 2, p1 

    Cancer induces a hypercoagulable state, and patients with cancer who suffer a thrombotic event have a worse prognosis than those who do not. Recurrent pathologic thrombi in patients with cancer are clinically managed with anticoagulant medications; however, anticoagulant prophylaxis is not...

  • Keeping anticoagulants under control. Hand, John // RN;Apr79, Vol. 42 Issue 4, p25 

    Focuses on the importance of keeping anticoagulants under control to prevent blood clot formation. Preventive measures for blood clot formation; Limitations in choosing anticoagulant drugs; Information on how anticoagulants prevent blood clots; Guidelines for average anticoagulant dosage.

  • Rivaroxaban reduces risk of death after MI.  // Medical Economics;1/10/2012, Vol. 89 Issue 1, p71 

    The article reports that oral anticoagulant rivaroxaban reduced the risk of death in a large randomized study.

  • Anticoagulant update - correction.  // British Dental Journal;9/28/2013, Vol. 215 Issue 6, p266 

    A correction to the letter to the editor on anticoagulant update is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics